Market News How it works Learn FAQ
| GPUS 0.1689 34.05% | XXII 0.1977 -8.34% | SHFS 0.1324 -61.39% | NVD 4.19 0.96% | LUCD 0.411 25.42% | SPCX 147.49 1.89% | T 20.93 -7.96% | SOXL 83.56 1.77% | NU 15.16 2.92% | NOK 8.14 3.30% | EWZ 42.59 1.77% | NVDA 210.96 -0.59% | RIME 0.106 -12.90% | INTC 86.96 1.72% | TSLG 4.87 -1.62% | AAL 12.11 -3.89% | BBD 4.07 3.04% | STLA 4.06 -4.81% | SOXS 52.46 -1.85% | RWM 14.55 0.34% | HYG 77.05 -0.06% | MYND 0.24 47.42% | BITO 10.83 -0.28% | SPDN 8.54 0.47% | YFOR 0.2236 -1.58% | RBNE 0.19 -2.56% | TQQQ 66.29 -0.20% | VZ 44.66 -1.19% | TSLL 9.76 -1.21% | SPTI 27.63 -0.11% | YMAT 2.05 6.77% | CRWV 54.235 -2.46% | INFY 12.35 -6.58% | RIG 6.41 5.43% | F 11.6 -2.85% | SQQQ 39.68 0.20% | AIOK 12.02 182.82% | ONDS 6.2 2.99% | AAPL 347.725 -0.14% | LABT 0.31 -36.67% | CDE 13.45 -3.10% | PCG 12.63 -2.70% | GRAB 2.79 -2.11% | SOFI 14.615 -1.05% | XLE 69.33 2.60% | IREN 24.905 -2.37% | QID 14.55 0.14% | RKT 11.73 -0.09% | WULF 11.32 0.00% | BE 193.3 -11.24%
ABAbCellera Biologics Inc. logo

AbCellera Biologics Inc. (ABCL)

NASDAQ Global Select · Currency in USD
$11.82 ▲ +0.45 (+3.96%)
At close: Oct 23, 4:00 PM ET. Market closed.
$11.74 ▼ -0.08 (-0.68%)
After hours: Oct 23, 7:58 PM ET

Summary

Previous Close
$11.37
Open
$11.45
Day's Range
$11.08 – $11.89
52 Week Range
$2.75 – $15.02
Volume
3,020,945
Avg. Volume
6,763,580
Market Cap
$3.83B
Beta (5Y Monthly)
1.19
PE Ratio (TTM)
--
EPS (TTM)
-$0.54
Earnings Date
Nov 9, 2026
Forward Dividend & Yield
--
Ex-Dividend Date
--
1y Target Est
$15.40

Profile: AbCellera Biologics Inc.

Sector
Healthcare
Industry
Biotechnology
Full-time employees
562
CEO
Carl Hansen

AbCellera Biologics Inc. specializes in pioneering an advanced platform for the discovery of antibodies. This comprehensive, AI-driven system meticulously explores and analyzes natural immune systems to identify antibodies suitable for the creation of new pharmaceutical drugs. As of December 31, 2021, the company had cultivated 156 discovery programs, ranging from completed to in-progress or under contract, in partnership with 36 entities.

Earnings

Next report: Mon, Nov 9, 2026
EPS estimate -$0.18 · Revenue est. $6.25M
DateEst.Actual
Aug 5, 2026-$0.16-$0.18Miss
May 11, 2026-$0.22-$0.14Beat
Feb 24, 2026-$0.18-$0.03Beat
Nov 6, 2025-$0.17-$0.19Miss
Aug 7, 2025-$0.17-$0.12Beat
May 8, 2025-$0.17-$0.15Beat

Analyst view

Consensus price target
$15.40 ▲ +30.3%
Range $7.00 – $30.00
Rating: Buy
Buy 92% · Hold 8% · Sell 0%

Similar stocks

Get free alerts on ABCL and big market moves

Free special alerts by text & email on new investment opportunities, buyouts and the stocks moving most, in plain English.
Get free stock alerts →
Data: Financial Modeling Prep. For information only, not investment advice.